Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBls Pharmaceuticals Limited

Bls Pharmaceuticals Limited

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.905 AUD -0.03 ( 3.21%)
Last update at 2026-11-12T05:10:00Z
VOLUME
172505
Market Cap
220.72M
P/E
13.36

Momentum Score

…

BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segment manufactures and distributes consumer health and novel food products under the Dr Watson brand. The Wholesale PCC/USA segment is involved in wholesale of patented Probiotics for gastrointestinal health and immunity. It also provides contract manufacturing services; and storage and distribution services. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.89
Low
0.94
High
52 Week Price Range
0.35
Low
1.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bls Pharmaceuticals Limited (ASX: BLS) is an Australian-listed company in the pharmaceutical/biotech sector, though public disclosure about its products and operations is limited. Long-term growth may be driven by successful product development, licensing or partnerships and broader healthcare demand, which could make the stock a way to gain exposure to pharmaceutical upside.

Key risks include limited information and transparency, clinical and regulatory approval uncertainty, small-cap liquidity and financing constraints, and commercial execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.94
Dividend Yield
-
Revenue TTM
73.91M
Revenue Per Share
0.33
Gross Profit TTM
39.48M
Debt / Equity
-
ROE
71.30%
Net Debt
-
ROCE
41.74%
Diluted EPS TTM
0.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2026-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 15.16M -12.97M -1.96M -0.24M
Minority interest - 0.18M - -
Net income 15.40M -13.33M -1.96M -0.24M
Selling general administrative 16.93M 2.98M 2.43M 0.90M
Gross profit 41.56M 3.40M 1.90M 1.29M
Reconciled depreciation 1.39M - 0.09M 0.05M
Operating income 15.80M -1.66M -2.14M -0.26M
Interest expense 0.46M - - 0.00M
Tax provision -0.24M 0.00M 0.00M 0.00M
Interest income 0.07M 0.02M 0.00M 0.02M
Net interest income -0.39M 0.02M 0.00M 0.01M
Total revenue 74.16M 9.33M 5.16M 2.42M
Cost of revenue 32.60M 5.93M 3.26M 1.13M
Total other income expense net -0.25M -11.33M 0.09M -0.04M
Net income from continuing ops 15.40M -12.97M -1.96M -0.24M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 52.08M - 6.70M 17.69M 2.92M
Intangible assets 0.39M - - - 0.03M
Other current assets - - - - 0.07M
Total liab 21.00M - 3.40M 2.69M 0.98M
Total stockholder equity 31.09M - 3.61M 15.14M 1.89M
Other current liab 2.66M - - - -
Capital stock 24.60M - 19.00M 17.55M 62.18M
Retained earnings 4.39M - -15.60M -2.48M -60.48M
Good will - - 0.29M 11.57M -
Cash 13.29M - 1.03M 3.85M 2.17M
Total current liabilities 14.22M - 2.91M 2.69M 0.98M
Short long term debt 1.09M - - - -
Total current assets 41.21M - 5.59M 6.04M 2.82M
Long term investments 0.17M - - - -
Net receivables 8.02M - 1.09M 0.90M 0.02M
Long term debt 1.93M - - - -
Inventory 17.82M - 2.14M 0.99M 0.31M
Accounts payable 7.13M - 1.19M 1.21M 0.10M
Non current assets total 10.88M - 1.11M 11.65M 0.10M
Capital lease obligations 5.41M - 0.67M - -
Breakdown 2026-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2026-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -0.09M - - -
Net borrowings 2.72M - 0.37M -
Total cash from financing activities 3.76M 1.21M 0.95M -
Net income 15.40M -13.33M -1.96M -0.24M
Change in cash 5.63M -2.84M 3.78M 0.43M
Begin period cash flow 7.67M 3.85M 0.07M 1.60M
End period cash flow 13.29M 1.03M 3.85M 2.17M
Issuance of capital stock 1.45M 1.35M 0.58M -
Capital expenditures 3.46M 0.49M 0.06M 0.01M
Free cash flow 1.95M -4.09M -1.19M 0.43M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BLS
Bls Pharmaceuticals Limited		 -0.03
3.21%		 0.91 13.36 - 2.99 7.10 2.91 12.70
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Bls Pharmaceuticals Limited

BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segment manufactures and distributes consumer health and novel food products under the Dr Watson brand. The Wholesale PCC/USA segment is involved in wholesale of patented Probiotics for gastrointestinal health and immunity. It also provides contract manufacturing services; and storage and distribution services. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited is headquartered in Sydney, Australia.

Level 5, Sydney, NSW, Australia, 2000

61 2 9078 8180

https://blspharma.com

Name Title Year Born
Mr. Samuel Watson CEO, MD & Executive Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD CFO & Company Secretary 1953
Mr. Jason Hine COO & Executive Director NA
Macdarragh O'Neill Head of Production of GMP & Director of BLS Wholesalers Pty NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…